Description
Brenzys is a prescription drug used for the treatment of various inflammatory conditions. Common indications include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
Brenzys is a soluble form of the p75 tumor necrosis factor (TNF) receptor administered via injection. Once in the bloodstream, it binds TNF alpha and TNF beta, causing biological TNF to become inactive. By inactivating TNF, Brenzys decreases the inflammatory response.
Directions
The usual dosage is 25-50 mg injected under the skin once or twice weekly. The length of therapy depends on the condition being treated.
Take Brenzys exactly as instructed by your doctor.
Ingredients
The active ingredient in Brenzys is etanercept.
Interactions
Common drug-drug interactions with this medication may include
- Abatacept
- Adenovirus Vaccine
- Anakinra
- Anifrolumab-fnia
- Bacillus of Calmette and Guerin Vaccine, Live
- Baricitinib
- Cholera Vaccine, Live
- Cyclophosphamide
- Dengue Tetravalent Vaccine, Live
- Infliximab
- Influenza Virus Vaccine, Live
- Measles Virus Vaccine, Live
- Mumps Virus Vaccine, Live
- Poliovirus Vaccine, Live
- Rilonacept
- Rotavirus Vaccine, Live
- Rubella Virus Vaccine, Live
- Smallpox Vaccine
- Typhoid Vaccine, Live
- Varicella Virus Vaccine, Live
- Vedolizumab
- Yellow Fever Vaccine
- Zoster Vaccine, Live
Cautions
Your doctor should test for tuberculosis (TB) before starting treatment.
All age-appropriate vaccinations should be completed before starting this drug.
Tell your doctor if you have a history of liver, kidney, heart, or neurologic disease before starting this drug.
Taking Brenzys can decrease the immune response and significantly increase the risk of infection.
Side Effects
Common side effects may include
- Aplastic anemia
- Autoimmune hepatitis
- Cancer
- Congestive heart failure
- Demyelinating disease of the central nervous system
- Erythema multiforme
- Hepatosplenic T-cell lymphoma
- Hypersensitivity reaction
- Infectious disease
- Injection site disorder
- Leukemia
- Malignant lymphoma
- Melanoma
- Multiple sclerosis
- Necrotizing fasciitis
- Optic neuritis
- Pancytopenia
- Peripheral demyelinating neuropathy
- Primary cutaneous vasculitis
- Reactivation of hepatitis B viral hepatitis
- Seizure
- Skin cancer
- Squamous cell carcinoma of skin
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Transverse myelitis, acute
- Tuberculosis
- Upper respiratory infection
References
Brenzys [package insert]. Kirkland, QC, Canada: Merck; August 2016.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14434